Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) continues to work with the British Columbia Securities Commission to address an ongoing continuous disclosure review. According to the update, the company has arranged for the following since the review commenced: Filing of business acquisition reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Update Regarding Ongoing Disclosure Review”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. Declared … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to Offer Esketamine for Treatment of Adults with MDD at Flagship Clinic”
Vast potential of mushroom medicine market is hindered by lack of pharma-grade extracts preventing brands from seizing this market opportunity Traditional extract producers limited by low-volume, non-scalable manufacturing methods Pure Extracts equipped to produce urgently needed pharma-grade psilocybin Pure Extracts, a Canadian plant-based extraction company operating in the functional medicinal mushrooms space, is in a … Continue reading “Pure Extract Technologies Inc. Focused on Becoming Dominant Extraction Company, Poised for Rapid Growth in Expanding Mushroom Market”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), on Friday announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission to complete its previously announced … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Files Acquisition Reports, Appoints New Director”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today issued a corporate update. Among other items highlighted in the update, the Company continues to work with the British Columbia Securities Commission (the “Commission”) to complete its continuous disclosure review. Champignon Brands will continue to fully cooperate with the Commission to assist in completion of the … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Corporate Update”
Disseminated on behalf of Helus Pharma Inc., may include paid advertisements. Investment Considerations HLP003 is in Phase 3 development with FDA Breakthrough Therapy Designation for adjunctive treatment of major depressive disorder. Twelve-month data following two 16 mg doses demonstrated sustained improvements in depression symptoms, including 100% responder and 71% remission rates in the analyzed cohort. … Continue reading “Helus Pharma Inc. (NASDAQ: HELP) (NEO: HELP)”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”). The review relates to Champignon’s disclosure obligations since it became a reporting issuer on … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Regulatory Review”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (“MDD”) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company today announced that … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc.’s (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Dr. McIntyre / CRTCE Published in Two Peer Reviewed Study Journals”
Pure Extracts is the development leader in the Canadian cannabis extract segment, which is valued by Deloitte at $2.7 billion annually. The Company is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products. The psychedelic and functional mushroom industries are among the … Continue reading “Pure Extracts Corp. is “One to Watch””
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Friday provided a corporate update. Since commencing trading on March 2, 2020, the Company has expanded its initiatives and rapidly executed on such initiatives to position it as a leading publicly traded psychedelic … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Provides Corporate Update”
